HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270008319793v1 48/8/926    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Frey, R. Articles by Wensing, G. Search for Related Content PubMed PubMed Citation Articles by Frey, R. Articles by Wensing, G. Social Bookmarking                         What's this?

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

From Clinical Pharmacology (Dr Frey, Dr Mück, Dr Artmeier-Brandt, Dr Weimann, Dr Wensing) and Global Biostatistics (Ms Unger), Bayer HealthCare AG, Pharma Research Centre, Wuppertal, Germany.

The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension. Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo. No serious adverse events were reported; there were no life-threatening events. Heart rate over 1 minute, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently versus placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01). Mean arterial and diastolic pressures were decreased versus placebo at doses of 1 mg (P < .05) and 5 mg (P < .01). Systolic pressure was not significantly affected. BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics. The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.

Key Words: Pulmonary hypertension • cyclic GMP • soluble guanylate cyclase • drug therapy • phase I clinical trial

Address for reprints: Dr Reiner Frey, Clinical Pharmacology, Bayer HealthCare AG, Pharma Research Centre, Aprather Weg 18a, 42096 Wuppertal, Germany; e-mail: reiner.frey{at}bayerhealthcare.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Grimminger, G. Weimann, R. Frey, R. Voswinckel, M. Thamm, D. Bolkow, N. Weissmann, W. Muck, S. Unger, G. Wensing, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Eur. Respir. J., April 1, 2009; 33(4): 785 - 792. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani and F. Grimminger Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Eur. Respir. Rev., March 1, 2009; 18(111): 35 - 41. [Abstract] [Full Text] [PDF]